ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / ACTU
KYNB (32) AKTX (37) MCRB (40) COCP (36) ⌘ Pro Terminal →

Actuate Therapeutics Inc. (ACTU) — RQD Stock Rating Cockpit

$0.34 +2.06% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.34

Actuate Therapeutics Inc. (ACTU) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $18.4M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ACTU Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ACTU stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Actuate Therapeutics Inc. (NASDAQ: ACTU) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $0.34 (+2.06% 1D, market cap $18.4M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ACTU ranks #609 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ACTU compare to KYNB and AKTX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ACTU carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, KYNB (Kyntra Bio Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $18.5M) and AKTX (Akari Therapeutics plc ADS) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $18.8M). Among the 5-stock peer group, ACTU leads on earnings multiple (N/A) while ACTU leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ACTU?
▼

Per ACTU's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001652935), Actuate Therapeutics Inc. generated $63.0M in revenue (-10.6% YoY), -$22.2M in net income, and -$19.2M in free cash flow against $14.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.34 (+0.18%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510035
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (6)Whales (5)SEC (10)Macro (9)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-11.8% Base Target
$8 Bull$0 Base$0 Bear
📬 FREE ACTU RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ACTU)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (35/100 Composite)
🔍 WHY ACTU SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (26% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 33.3 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
43
Grade D$0.47+31.9% Next Q
Q2 (-2Q)
40
Grade D$0.62-35.5% Next Q
Q3 (-1Q)
38
Grade E$0.40-15% Next Q
Current
35
Grade D-$0.34-8.5% Hist 90D α
Trajectory: D (43) → D- (35)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ACTU Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ACTU currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.87) and Max Pain ($0.36) forces dealer call-delta covering toward $8.29.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ACTU• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ACTU Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 35%NO 65%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
33.330 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
3 / 99-Pt Accounting
52-WEEK LASER RANGE2% OF RANGE
L: $0$0.34H: $8
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 6 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 10 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 19 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on ACTU

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (30)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (32)

10/40 institutional & smart-money positioning score with 9/20 macro alignment.

Bull Case: Why Buyers Like ACTU
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ACTU)

  • ✓Walkthrough of ACTU's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ACTU // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -88.47%🛡️ HOLDING TREND SUPPORT
2026-11-03O $0.38H $0.38L $0.34C $0.34VOL 489.5K
RES: $1.04SUP: $0.26SMA50: $0.87SMA200: $2.11
$6.05$4.50$2.95$1.40$-0.15RES $1.04SUP $0.26$0.342026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ACTU Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ACTU Butterfly Map → + Track ACTU →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -10.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ACTU today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ACTU. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ACTU today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ACTU)

Health Care Rank #609 of 1015 ⚔️ KYNB vs ACTU Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ACTU vs. KYNB, AKTX, MCRB, COCP)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Actuate Therapeutics Inc. (ACTU) ranks #609 by composite RQD confidence (35/100, grade D-) and #835 by equity capitalization ($18.4M). Within this direct 5-issuer industry benchmark cohort, ACTU leads on earnings valuation at N/A trailing P/E, while ACTU leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. MCRB currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with ACTU at 35/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ACTU ACTIVE
Actuate Therapeutics Inc.
D- 35/100 — — -35.0% +2.06% $18.4M Benchmark Subject
KYNB
Kyntra Bio Inc.
E 32/100 — 91.4% -35.0% -2.41% $18.5M /kynb-vs-actu →
AKTX
Akari Therapeutics plc ADS
D- 37/100 — — -35.0% -4.85% $18.8M /aktx-vs-actu →
MCRB
Seres Therapeutics Inc.
D- 40/100 — — -35.0% +3.39% $17.8M /mcrb-vs-actu →
COCP
Cocrystal Pharma Inc.
D- 36/100 — — -35.0% +6.53% $19.2M /cocp-vs-actu →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001652935 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Actuate Therapeutics Inc. (ACTU) reported GAAP revenue of $63.0M (-10.6% vs. FY2024 revenue of $70.5M , and -9.9% cumulative change since FY2023) , GAAP net income of -$22.2M, operating cash flow of -$19.2M, and free cash flow of -$19.2M (+12.1% YoY). On the balance sheet, ACTU closed FY2025 with $14.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $63.0M -$22.2M -$19.2M -$19.2M $14.0M —
FY2024 (FY) 2024-12-31 $70.5M -$27.3M -$21.8M -$21.8M $9.3M —
FY2023 (FY) 2023-12-31 $69.9M -$24.7M -$21.6M -$21.6M — —

3. ACTU Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ACTU stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Actuate Therapeutics Inc. (NASDAQ: ACTU) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $0.34 (+2.06% 1D, market cap $18.4M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ACTU ranks #609 in composite RQD confidence.

How does ACTU compare to KYNB and AKTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ACTU carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, KYNB (Kyntra Bio Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $18.5M) and AKTX (Akari Therapeutics plc ADS) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $18.8M). Among the 5-stock peer group, ACTU leads on earnings multiple (N/A) while ACTU leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ACTU?

Per ACTU's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001652935), Actuate Therapeutics Inc. generated $63.0M in revenue (-10.6% YoY), -$22.2M in net income, and -$19.2M in free cash flow against $14.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ACTU trading relative to its 50-day, 200-day, and 52-week technical levels?

ACTU last traded at $0.34 (+2.06% on volume of 295,536 shares), positioning the stock -60.92% below its 50-day simple moving average ($0.87) and -83.89% below its 200-day simple moving average ($2.11). Across its 52-week range of $0.33 to $7.90, ACTU sits at the 0.1% percentile with a 14-day RSI of 33.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.38).

Direct Sub-Reports: ACTU RQD Cockpit ACTU 12M Forecast ACTU Earnings & Move ACTU Dividends & DRIP ACTU Insiders & 13F ACTU Whale Options ACTU Profit Sankey ACTU News & Why
ROARABLE RATING BRIEF • RQD 35/100 (D-) ✓ SEC XBRL & RQD VERIFIED

ACTU — Actuate Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Actuate Therapeutics Inc. (ACTU) earns a live Roarable RQD composite score of 35/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.34 (+2.06% 1D, market capitalization $18.4M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Actuate Therapeutics Inc. Is a NASDAQ-listed issuer classified under the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry,. The FY 2025 and FY 2024 revenue figures are reported as —, and the company's model of monetization is not detailed in the sources.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Actuate Therapeutics Inc. (ACTU) reported $63.0M in annual revenue (up from $70.5M in FY2024, -10.6% YoY) and -$22.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($69.9M revenue, -$24.7M net income) through FY2025, ACTU scaled operating cash flow to -$19.2M and free cash flow to -$19.2M, backed by $14.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 35/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 5/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $0.33 – $7.90 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies cannot be identified from the source data. A prospective investor should note that the absence of mapped links means second-order bottlenecks cannot be assessed here, and any ripple analysis would require information outside this source set.

  • Key Question #1: Can ACTU sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $63.0M and free cash flow of -$19.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is ACTU's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ACTU Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Actuate Therapeutics Inc. (ACTU) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ACTU Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ACTU Bull vs. Bear Conversation Board — What's Your Call at $0.34?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ACTU 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ACTU:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $0.44 (+29.4%)
📌 Pinned Debate

Recent financings priced an $11.0 Million underwritten offering and a $9.96 Million stock-and-warrant raise, which bolster the cash bal

Picked up a starter position in ACTU in my $100K Virtual Cash book at $0.34. Recent financings priced an $11.0 Million underwritten offering and a $9.96 Million stock-and-warrant raise, which bolster the cash balance of $13.2M.. Trading inside a $0.33–$7.90 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

VolSurface_Trader 🐂 BULL

Both sides have a point here — ACTU's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $0.28 (-17.6%)
Spot @ $0.34

The company reports ROIC of -35%, zero revenue, and negative free cash flow of -$19.2M, with the stock down to $0.37 from a 52-week hig

The company reports ROIC of -35%, zero revenue, and negative free cash flow of -$19.2M, with the stock down to $0.37 from a 52-week high of $7.9.. Look at the math on ACTU: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $0.30 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%